Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Teva Pharmaceutical (TEVA)
NYSE:TEVA
RESEARCH TOOLSreports
TEVA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$11.48 - $22.80
Previous CloseN/A
Volume1.13M
Average Volume (3M)11.09M
Market Cap
$24.54B
Enterprise Value$36.69B
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.48
Next Earnings
Jan 29, 2025EPS Estimate
0.7Last Dividend Ex-Date
Nov 27, 2017Dividend YieldN/A
Share Statistics
EPS (TTM)-0.85
Shares Outstanding1,134,592,400
10 Day Avg. Volume9,960,903
30 Day Avg. Volume11,089,281
Standard Deviation0.11
R-Squared0.11
Alpha0.01
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)1.46
Price to Cash Flow (P/CF)8.90
P/FCF Ratio11.30
Enterprise Value/Market Cap1.50
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit4.80
Enterprise Value/Ebitda18.12
Forecast
1Y Price Target
$24.50Price Target Upside45.75% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
---
Bulls Say, Bears Say
Bulls Say
Financial PerformanceTeva delivered 3Q consensus revenue and EBITDA beats and raised its FY24 outlook reflecting strength of the business.
Product DevelopmentRecent positive Ph2 data for duvakitug in UC and Crohn’s seen as a major surprise with potential for further development in fibrotic disorders.
Revenue GrowthHigh margin brands like Austedo and Ajovy are expected to add significant sales, offsetting future headwinds.
Bears Say
Financial PerformanceTeva's price objective was reduced due to lower expected margins, despite negligible changes in topline estimates.
Market ChallengesTeva flagged uncertain competitive dynamics as a net pricing variable for generics, particularly g-Revlimid.
Strategic ConcernsThe phase 3 program timelines would be behind competitors MRK and Roche.
---
Ownership Overview
0.42% Insiders
6.60% Mutual Funds
0.25% Other Institutional Investors
89.60% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
TEVA FAQ
What was Teva Pharmaceutical’s price range in the past 12 months?
Teva Pharmaceutical lowest stock price was $11.48 and its highest was $22.80 in the past 12 months.
What is Teva Pharmaceutical’s market cap?
Teva Pharmaceutical’s market cap is $24.54B.
When is Teva Pharmaceutical’s upcoming earnings report date?
Teva Pharmaceutical’s upcoming earnings report date is Jan 29, 2025 which is 13 days ago.
How were Teva Pharmaceutical’s earnings last quarter?
Teva Pharmaceutical released its earnings results on Jan 29, 2025. The company reported $0.71 earnings per share for the quarter, beating the consensus estimate of $0.707 by $0.003.
Is Teva Pharmaceutical overvalued?
According to Wall Street analysts Teva Pharmaceutical’s price is currently Undervalued.
Does Teva Pharmaceutical pay dividends?
Teva Pharmaceutical pays a Quarterly dividend of $0.072 which represents an annual dividend yield of N/A. See more information on Teva Pharmaceutical dividends here
What is Teva Pharmaceutical’s EPS estimate?
Teva Pharmaceutical’s EPS estimate is 0.7.
How many shares outstanding does Teva Pharmaceutical have?
Teva Pharmaceutical has 1,134,592,400 shares outstanding.
What happened to Teva Pharmaceutical’s price movement after its last earnings report?
Teva Pharmaceutical reported an EPS of $0.71 in its last earnings report, beating expectations of $0.707. Following the earnings report the stock price went down -13.888%.
Which hedge fund is a major shareholder of Teva Pharmaceutical?
Among the largest hedge funds holding Teva Pharmaceutical’s share is Slate Path Capital LP. It holds Teva Pharmaceutical’s shares valued at 246M.
---
Teva Pharmaceutical Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$24.50 (45.75% Upside)
$24.50 (45.75% Upside)
Blogger Sentiment
Bullish
TEVA Sentiment 83%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 1.3M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $6.3M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 1.0%
Last 30 Days ▲ 0.7%
Last 30 Days ▲ 0.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
81.11%
12-Months-Change
Fundamentals
Return on Equity
-16.36%
Trailing 12-Months
Asset Growth
-0.78%
Trailing 12-Months
Company Description
Teva Pharmaceutical
Teva Pharmaceutical Industries Ltd. engages in the development and production of medicines. Its products include medicines for cardiovascular diseases, pain relievers, obesity, cancer and supportive care, infectious diseases and human immunodeficiency viruses, and colds and coughs. The company was founded in 1901 and is headquartered in Petah Tikva, Israel.
---
TEVA Company Deck
---
TEVA Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call reflected a strong performance in key products and business segments, alongside improvements in credit ratings, but also highlighted challenges such as the impact of macroeconomic factors and the future decline in Revlimid revenue. Despite these challenges, Teva remains optimistic about its growth strategy and product pipeline.Read More>---
TEVA Revenue Breakdown
54.45% North America
32.42% Europe
13.12% International Markets
---
TEVA Stock 12 Month Forecast
Average Price Target
$24.50
▲(45.75% Upside)
Technical Analysis
Best Analysts Covering TEVA
1 Year
1 Year Success Rate
12/24 ratings generated profit
1 Year Average Return
+19.88%
reiterated a buy rating 13 days ago
Copying Balaji Prasad's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +19.88% per trade.
---